Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · IEX Real-Time Price · USD
21.26
+0.07 (0.33%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 32.17, with a low estimate of 25 and a high estimate of 37. The average target predicts an increase of 51.32% from the current stock price of 21.26.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 3, 2024.
Analyst Ratings
The average analyst rating for CSTL stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 6 | 6 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 9 | 9 | 9 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $33 → $34 | Buy | Maintains | $33 → $34 | +59.92% | May 3, 2024 |
| Keybanc | Keybanc | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +31.70% | Mar 1, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $33 → $37 | Buy | Maintains | $33 → $37 | +74.04% | Mar 1, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +17.59% | Dec 14, 2023 |
| Keybanc | Keybanc | Buy Maintains $37 → $25 | Buy | Maintains | $37 → $25 | +17.59% | Aug 4, 2023 |
Financial Forecast
Revenue This Year
265.74M
from 219.79M
Increased by 20.91%
Revenue Next Year
266.48M
from 265.74M
Increased by 0.28%
EPS This Year
-1.65
from -2.14
EPS Next Year
-1.95
from -1.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 277.4M | 286.7M | 327.6M | 342.2M | 384.5M |
| Avg | 265.7M | 266.5M | 303.4M | 332.0M | 366.1M |
| Low | 250.9M | 235.2M | 282.7M | 318.5M | 344.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.2% | 7.9% | 22.9% | 12.8% | 15.8% |
| Avg | 20.9% | 0.3% | 13.8% | 9.4% | 10.3% |
| Low | 14.1% | -11.5% | 6.1% | 5.0% | 3.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.43 | -1.09 | -0.19 | -0.03 | 0.80 |
| Avg | -1.65 | -1.95 | -1.15 | -0.25 | 0.32 |
| Low | -1.92 | -3.00 | -2.33 | -0.45 | -0.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.